PET/MRI用于胰腺癌患者的评估
胰腺癌是美国癌症相关死亡的第三大原因,尽管影像和治疗模式有所改善,预后仍然不佳。CT和MRI常用于分期和再分期,PET/CT可在疑难时发挥作用并改善全身分期。PET/MRI是一种新型成像方式,可同时采集PET和MRI图像,提高图像质量并可能增加敏感性;早期研究提示PET/MRI未来可能在胰腺癌成像中发挥更大作用。
要点
- CT和MRI常用于胰腺癌分期和再分期,PET/CT可在疑难时发挥作用并改善全身分期。
- PET/MRI可同时采集PET和MRI图像,提高图像质量并可能增加敏感性。
- 早期研究提示PET/MRI未来可能在胰腺癌成像中发挥更大作用。
核心结论
- PET/MRI是一种新型成像方式,可同时采集PET和MRI图像,提高图像质量并可能增加敏感性;早期研究提示PET/MRI未来可能在胰腺癌成像中发挥更大作用。
研究设计与样本
- 本文为综述,讨论当前胰腺癌成像方法并概述支持PET/MRI用于胰腺癌的现有证据和已发表数据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Pancreatic cancers are the third leading cause of cancer-related death in the USA and outcomes remain poor despite improvements in imaging and treatment paradigms. Currently, computed tomography (CT) and magnetic resonance imaging (MRI) are frequently utilized for staging and restaging of these malignancies, but positron emission tomography (PET)/CT can play a role in troubleshooting and improve whole-body staging. PET/MRI is a novel imaging modality that allows for simultaneous acquisition of PET and MRI images, leading to improved image quality and potential increased sensitivity. Early studies suggest that PET/MRI may play a larger role in pancreatic cancer imaging in future. This manuscript will briefly discuss current imaging approaches to pancreatic cancer and outline existing evidence and published data supporting the use of PET/MRI for pancreatic cancers.
引用
- Duncan, Summerlin, West, et al. PET/MRI for evaluation of patients with pancreatic cancer. Abdom Radiol (NY). 2023. PMID: 37191756. doi:10.1007/s00261-023-03943-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。